Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study
| Autor: | Nicole G. M. Hunfeld, Henrik Endeman, Tim M J Ewoldt, Suzanne Polinder, Diederik Gommers, Anouk E. Muller, Alan Abdulla, Birgit C. P. Koch |
|---|---|
| Přispěvatelé: | Intensive Care, Pharmacy, Medical Microbiology & Infectious Diseases, Public Health |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Total cost medicine.medical_treatment critically ill Critical Illness Antibiotics MEDLINE target attainment beta-Lactams 030226 pharmacology & pharmacy law.invention Health administration 03 medical and health sciences 0302 clinical medicine law antibiotic Health care medicine Humans Pharmacology (medical) Renal replacement therapy Retrospective Studies Pharmacology business.industry microcost Health Care Costs Length of Stay Intensive care unit Anti-Bacterial Agents Intensive Care Units Cost driver Emergency medicine ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Original Article business beta-lactam |
| Zdroj: | Therapeutic Drug Monitoring Therapeutic Drug Monitoring, 44(1), 224-229. Lippincott Williams & Wilkins |
| ISSN: | 1536-3694 0163-4356 |
| Popis: | Supplemental Digital Content is Available in the Text. Background: Optimizing beta-lactam antibiotic treatment is a promising method to reduce the length of intensive care unit (ICU) stay and therefore reduce ICU costs. We used data from the EXPAT trial to determine whether beta-lactam antibiotic target attainment is a cost determinant in the ICU. Methods: Patients included in the EXPAT trial were divided into target attainment and target nonattainment based on serum antibiotic levels. All hospital costs were extracted from the hospital administration system and categorized. Results: In total, 79 patients were included in the analysis. Target attainment showed a trend toward higher total ICU costs (€44,600 versus €28,200, P = 0.103). This trend disappeared when correcting for ICU length of stay (€2680 versus €2700). Renal replacement therapy was the most important cost driver. Conclusions: Target attainment for beta-lactam antibiotics shows a trend toward higher total costs in ICU patients, which can be attributed to the high costs of a long stay in the ICU and renal replacement therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|